Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Lori Muffly(Stanford University), William A. Wood(University of North Carolina at Chapel Hill), Mohamed L. Sorror(University of Washington Medical Center), Attaphol Pawarode(University of Michigan), Frédéric Baron(University of Liège), Ashish Bajel(The Royal Melbourne Hospital), Edward A. Copelan(Levine Cancer Institute), Gerhard Hildebrandt(University of Missouri Health System), Rodrigo Martino(Universitat Autònoma de Barcelona), Marlise R. Luskin(Dana-Farber Cancer Institute), Saurabh Chhabra(Medical College of Wisconsin), Ann A. Jakubowski(Memorial Sloan Kettering Cancer Center), Yi‐Bin Chen(Massachusetts General Hospital), Jeff Szer(The Royal Melbourne Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Harry C. Schouten, James M. Foran(Memorial Sloan Kettering Cancer Center), Anita D’Souza, Amer Beitinjaneh(University of Miami), Hillard M. Lazarus(University Hospitals of Cleveland), César O. Freytes(CHRISTUS Transplant Institute), Shahrukh K. Hashmi(Mayo Clinic), Karen K. Ballen(University of Virginia Health System), Mathew Carabasi(Thomas Jefferson University Hospital), Sachiko Seo(National Cancer Center Hospital East), Xiaochun Zhu, David A. Rizzieri(Duke University), Taiga Nishihori(Moffitt Cancer Center), Philip L. McCarthy(Roswell Park Comprehensive Cancer Center), Baldeep Wirk(Boston University), Mitchell Sabloff(University of Ottawa), Ruta Brazauskas(Medical College of Wisconsin), Rebecca L. Olin(University of California, San Francisco), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Andrew R. Rezvani(Stanford Blood Center), Richard F. Olsson(AstraZeneca (Netherlands)), Minoo Battiwalla(Sarah Cannon), Kehinde Adekola(Northwestern Memorial Hospital), Richard T. Maziarz(Oregon Health & Science University), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Marcelo C. Pasquini(Cleveland Clinic), Robert Peter Gale(Imperial College London), Bipin N. Savani(Vanderbilt University Medical Center), Stefan O. Ciurea(University of California, Irvine), John Edwards(Indiana Cancer Consortium), Jean‐Yves Cahn(Université Grenoble Alpes), Henry C. Fung(Fox Chase Cancer Center), Michael J. Martens(Medical College of Wisconsin), Edward Peres(Henry Ford Hospital), Matthew D. Seftel(CancerCare Manitoba)
Cited by 296
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k